Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical enters into Agreement for Manufacturing and Marketing Authorization and related Marketing Rights for Wellnara® Combination Tablets

TOKYO, November 4, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi) announced that its subsidiary, ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi; hereinafter "ASKA Pharmaceutical"), has entered into an agreement regarding the transfer of the manufacturing and marketing authorization and related marketing rights in Japan for Wellnara® Combination Tablets (hereinafter "the Product"), an oral estradiol-progestin combination therapy for postmenopausal osteoporosis currently marketed by Bayer Yakuhin, Ltd. (Head Office: Osaka; President and Representative Director: Ashraf Al-Ouf).

Under the agreement, ASKA Pharmaceutical plans to assume the manufacturing and marketing authorization for the Product. The timing of the marketing authorization transfer will be announced once determined. Following completion of the transfer, ASKA Pharmaceutical will work to maintain and secure a stable and continuous supply of the Product, while further advancing its initiatives to address the diverse healthcare needs of women.

Until the transfer is completed, the existing manufacturing, marketing, and sales arrangements will remain in place. ASKA Pharmaceutical will not be involved in any activities relating to the Product, including activities to promote the appropriate use of the product, until completion of the transfer.

The impact of this matter on the consolidated financial results of ASKA Pharmaceutical Holdings Co., Ltd. for the current fiscal year is expected to be immaterial. If any matter requiring disclosure arises, the Company will promptly make an announcement.

Product Subject to the Transfer

Product Name	Wellnara® Combination Tablets
Generic Name	Estradiol and Levonorgestrel Tablets
Indications	Postmenopausal Osteoporosis

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Group Management Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp